Lipids & metabolic liver disease
Dual modulation of lipid and glucose metabolism by a nutraceutical combination in patients at cardiometabolic risk: results from a multicenter randomized controlled trial
Primary result · Reduction in glycemic levelsResult — go to the resultb - 16Authors' conclusion
Taken together, our findings indicate that the treatment with a NUT combination containing Morus alba simultaneously reduces plasma levels of LDL-C and glucose.
Study context
- Population
- Patients at cardiometabolic risk
- Participants
- 359 patients
- Comparison
- NUT with Monacolin K (MK) and Morus alba vs NUT with MK alone
- F2n = 189
- F1n = 170reference
- Primary endpoint
- Association between LDL-C-lowering therapy and glycemia
- Follow-up
- 3 months
Methodological detailsmulticentre, prospective, active-treatment controlled
- Multicentre
- Prospective
- Active-treatment controlled
Primary result
Reduction in glycemic levels
b
- 16
P < 0.001
As reported in the abstract
Further findings
Association between LDL-C and glycemic levels over time
- Significant direct association between LDL-C and glycemic levels in F2 (b)
- 0.06, p = 0.002
- Inverse relationship between LDL-C and glycemic levels in F1
Original publication
Dual modulation of lipid and glucose metabolism by a nutraceutical combination in patients at cardiometabolic risk: results from a multicenter randomized controlled trial. Cardiovasc Diabetol. Published 3 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →